Table 1.
Summary of patient characteristics for the study cohort
| Study cohort | ||
|---|---|---|
| n | % | |
| Randomised treatment | ||
| E-CMF | 1156 | 19 |
| CMF | 1149 | 19 |
| EC-T | 1773 | 28 |
| EC-TG | 1769 | 28 |
| T-EC | 200 | 3 |
| TG-EC | 201 | 3 |
| Age, years | ||
| ≤ 50 | 3606 | 58 |
| > 50 | 2642 | 42 |
| ER status | ||
| Negative | 2551 | 41 |
| Positive | 3591 | 57 |
| Missing | 106 | 2 |
| pGR status | ||
| Negative | 2463 | 39 |
| Positive | 2652 | 43 |
| Missing | 1133 | 18 |
| HER2 status | ||
| Negative | 3760 | 60 |
| Positive | 1034 | 17 |
| Missing | 1454 | 23 |
| Nodal status | ||
| Negative | 1366 | 22 |
| 1–3 positive | 2383 | 38 |
| Clinically negative, neoadjuvant | 409 | 7 |
| Clinically positive, neoadjuvant | 403 | 6 |
| 4+ positive | 1687 | 27 |
| Breast cancer-specific survival | ||
| Breast cancer related deaths | 1335 | 21 |
| Deaths due to other cause | 148 | 2 |
| Alive | 4765 | 77 |
| Relapse-free survival | ||
| Events | 1888 | 30 |
| Censored | 4360 | 70 |
| Triple negative status | ||
| No (ER+ and HER2–) | 2321 | 37 |
| Yes (ER–, PGR– or unknown, and HER2–) | 1242 | 20 |
| Missing | 2685 | 43 |
| ECOG performance status | ||
| 0 | 5232 | 84 |
| ≥ 1 | 683 | 11 |
| Missing | 333 | 5 |
| Tumour size, mm | ||
| 0–20 | 2195 | 35 |
| 21–50 | 3375 | 54 |
| > 50 | 475 | 8 |
| Missing | 203 | 3 |
| Tumour grade | ||
| 1 | 146 | 2 |
| 2 | 2206 | 35 |
| 3 | 3654 | 59 |
| Missing | 242 | 4 |
| Menopausal status | ||
| Pre/peri | 3480 | 56 |
| Post | 2200 | 35 |
| Missing | 568 | 9 |
| BMI | ||
| Underweight (<18.5) | 69 | 1 |
| Healthy weight (18.5 to <25) | 2503 | 40 |
| Overweight (25 to <30) | 2088 | 33 |
| Obese (≥30) | 1469 | 24 |
ER Estrogen receptor; pGR Progesterone receptor; HER2 Human epidermal growth factor receptor; ECOG Eastern Co-operative Oncology Group; BMI Body mass index; E Epirubicin; C Cyclophosphamide; M Methotrexate; F 5-fluouroucil; T Paclitaxel; G Gemcitabine